sharktank image
Alternative Medicinefeatured_memberLiving With CFResearch

Sharktank: Jim Caldwell

My name is Jim Caldwell and I would like to introduce myself to this group. I am the president of another cystic fibrosis group called Sharktank Research Foundation (sharktank.org). I’ve been involved with Sharktank since 1999. I began studying cystic fibrosis seventeen years ago through Sharktank, shortly after my daughter was …

READ MORE →
Lancet logo
GeneticsLiving With CFResearchTreatments

Trial results of Ivacaftor in Cystic Fibrosis children ages 2-5

Results are out from a two part study involving children ages 2-5 with at least one gating mutation trying Ivacaftor (a medication used in Cystic Fibrosis treatment) From the Lancet Respiratory Journal, 20 January 2016 Ivacaftor has been shown to be a safe, effective treatment for cystic fibrosis in patients …

READ MORE →
crispr
GeneticsLiving With CFResearchVideo

Genome editing with CRISPR-Cas9

This video explains how research in genome editing may help treat genetic diseases like CF in the future.

READ MORE →
imgres
Living With CFResearchTechnology

Personal Spirometry and the Cystic Fibrosis Patient

Written by Jeanne Barnett As a moderator/founder of a vibrant online social health community: cysticfibrosis.com, I can attest to hundreds of messages in which cystic fibrosis e-patients discuss their PFTs (pulmonary function tests). Members are so in tune with these numbers, they often add them to their signatures along with …

READ MORE →
gene-mutations-in-CF
GeneticsLiving With CFResearch

Cystic Fibrosis genetics: Know Your CF Mutations

Source: CFF.org For the first time, drugs are available that treat the underlying cause of the disease in people with certain cystic fibrosis mutations. As new therapies targeting specific mutations of Cystic Fibrosis genetics are developed and become available, it will be increasingly important to know your mutations so you …

READ MORE →
shutterstock_156419843-770x470
Living With CFResearchRespiratory DiseaseTreatments

Concert Pharma’s Modified Version of Cystic Fibrosis Therapy Ivacaftor Outperforms Kalydeco in Early Testing

Written by Patricia Inacio, PhD Source: Cystic Fibrosis News Today Concert Pharma recently announced successful results from a Phase 1 single ascending dose clinical trial for their lead investigational drug CTP-656 as a therapy for cystic fibrosis. Cystic fibrosis is a life-threatening disease characterized by a progressive lung function decline and is caused …

READ MORE →